During influenza season, which children need an antiviral and which one should I prescribe? Do I need to verify that they have influenza first?

Paediatrics and Child Health

Volumn 15, Issue 8, 2010, Pages 499-501

  Bowman, M ^a   Forgie, S E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; ZANAMIVIR;

ANTIVIRAL THERAPY; BRONCHOSPASM; CHILD; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; PRESCRIPTION; REVIEW; TREATMENT INDICATION; VOMITING;

EID: 78349288837     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/15.8.499     Document Type: Review

References (33)

1. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006;(2):CD001169.
2. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;(1):002744.
3. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33.
4. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005;24:225-32. (Pubitemid 40365856)
5. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial. Pediatr Infect Dis J 2000;19:410-7. (Pubitemid 30307990)
6. A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic Influenza A and/or B infection. GlaxoSmithKline [revised NAI30028].
7. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: Systematic review and meta-analysis of randomised controlled trials. BMJ 2009;339:b3172.
8. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006;194(Suppl 2):S133-8.
9. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships. Int J Risk Saf Med 2008;20:5-36. (Pubitemid 351526058)
10. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. MedGenMed 2007;9:23. (Pubitemid 350031662)
11. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009;21:79-89.
12. Roche Canada. Product Monograph - Tamiflu. 〈www.rochecanada.com/ gear/glossary/servlet/staticfilesServlet?type=data&communityId= re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile-10122. pdf〉 (Accessed on April 26, 2010).
13. Roche USA. Tamiflu Package Insert. 〈www.rocheusa.com/products/ tamiflu/〉 (Accessed on April 19, 2010).
14. Okamoto S, Kamiya I, Kishida K, et al. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005;24:575-6. (Pubitemid 40847541)
15. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2010;29:195-8.
16. Williamson JC, Pegram PS. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med 2002;1:85-90. (Pubitemid 37038926)
17. Burton C, Vaudry W, Moore D, et al. Children hospitalized with influenza during the 2006-2007 season: A report from the Canadian Immunization Monitoring Program, Active (IMPACT). Canada Communicable Dis Report 2008;34:17-9.
18. Public Health Agency of Canada. FluWatch. 〈www.phac-aspc.gc.ca/ fluwatch/09-10/w44-09/index-eng.php〉 (Accessed on April 19, 2010).
19. BNet. Pediatric oseltamivir stockpile drained as H1N1 deaths rise. 〈http://findarticles.com/p/articles/mi-hb4384/is-11-43/ai-n42549679/〉 (Accessed on April 19, 2010).
20. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario. Clin Infect Dis 2007;45:1568-75. (Pubitemid 351411840)
21. Lee N, Chan PK, Hui Ds, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;200:492-500.
22. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. The new influenza A virus: A/Mexico/2009 (H1N1) practice point for caregivers of children and youth. 〈www.cps.ca/english/statements/ID/ H1N1Mexico2009.htm〉 (Accessed on April 19, 2010).
23. Public Health Agency of Canada. Guidance for ambulatory care of influenza-like illness in the context of pandemic (H1N1) 2009 influenza virus. 〈www.phac-aspc.gc.ca/alert-alerte/h1n1/guidanceorientation-amb-07-16-eng. php〉. (Accessed on June 2, 2010).
24. Costello BE, Simon HK, Massey R, Hirsh P. Pandemic H1N1 influenza in the pediatric emergency department: A comparison with previous seasonal influenza outbreaks. Ann Emerg Med 2010.
25. O'Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Risk factors and outcomes among children admitted to hospital with pandemic H1N1. CMAJ 2009;182:384.
26. Hawkes M, Richardson SE, Ipp M, et al. Sensitivity of rapid influenza diagnostic testing for swine-origin 2009 A (H1N1) influenza virus in children. Pediatrics 2010;125:e639-e644.
27. Hackett S, Hill L, Patel J, et al. Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet 2009;374:605.
28. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92.
29. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009;301:1034-41.
30. WHO. Pandemic (H1N1) 2009. 〈www.who.int/csr/disease/swineflu/ laboratory30-12-2009/en/index.html〉 (Accessed on April 16, 2010).
31. Genentech. Tamiflu. 〈www.gene.com/gene/products/information/ tamiflu〉 (Accessed on April 16, 2010).
32. Parker RM, Wolf MS, Jacobson KL, Woods AJJ. Risk of confusion in dosing Tamiflu oral suspension in children. N Engl J Med 2009;361:1912.
33. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Managing seasonal and pandemic influenza in infants, children and youth. 〈www.cps.ca/english/publications/SeasonalPandemicFlu.pdf〉 (Accessed on September 8, 2010).